Blueprint Medicines Corp (NASDAQ:BPMC) Director Lonnel Coats Sells 10,000 Shares
Blueprint Medicines Corp (NASDAQ:BPMC) Director Lonnel Coats sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $82.40, for a total value of $824,000.00. Following the completion of the sale, the director now directly owns 10,000 shares in the company, valued at approximately $824,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
BPMC traded down $2.79 on Monday, hitting $81.27. 557,654 shares of the company were exchanged, compared to its average volume of 461,085. The firm has a fifty day simple moving average of $94.73 and a two-hundred day simple moving average of $84.41. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.52 and a current ratio of 7.52. Blueprint Medicines Corp has a 12 month low of $44.58 and a 12 month high of $102.98. The stock has a market capitalization of $4.13 billion, a PE ratio of -15.08 and a beta of 1.55.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.92) by ($0.12). Blueprint Medicines had a negative return on equity of 73.73% and a negative net margin of 4,268.74%. The company had revenue of $5.11 million for the quarter, compared to the consensus estimate of $1.39 million. During the same quarter in the previous year, the business earned ($0.62) earnings per share. Blueprint Medicines’s revenue was down 87.7% compared to the same quarter last year. On average, equities analysts expect that Blueprint Medicines Corp will post -8.45 earnings per share for the current year.
Several analysts have weighed in on the company. Raymond James reaffirmed a “market perform” rating on shares of Blueprint Medicines in a report on Wednesday, August 14th. Deutsche Bank started coverage on Blueprint Medicines in a report on Thursday, July 18th. They issued a “buy” rating and a $110.00 price target on the stock. ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 4th. BidaskClub cut Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Finally, Canaccord Genuity raised their price objective on Blueprint Medicines from $105.00 to $120.00 and gave the company a “buy” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $110.11.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Story: How do buyers and sellers choose a strike price?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.